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HIV-1 replication can be eﬃciently inhibited by intracellular expression of an siRNA targeting the viral RNA. We used a well-
validated siRNA (si510) which targets the poly A/TAR (transactivator of the HIV-1 LTR) site and suppresses viral replication.
Nanotechnology holds much potential for impact in the ﬁeld of HIV-1 therapeutics, and nanoparticles such as quantum rods
(QRs) can be easily functionalized to incorporate siRNA forming stable nanoplexes that can be used for gene silencing. We
evaluated the eﬃcacy of the QR-si510 HIV-1 siRNA nanoplex in suppressing viral replication in the HIV-1-infected monocytic
cell line THP-1 by measuring p24 antigen levels and gene expression levels of HIV-1 LTR. Our results suggest that the QR-si510
HIV-1 siRNA nanoplex is not only eﬀective in delivering siRNA, but also in suppressing HIV-1 viral replication for a longer time
period. HIV-1 nanotherapeutics can thus enhance systemic bioavailability and oﬀer multifunctionality.
1.Introduction
Treatment of human immunodeﬁciency virus type 1 (HIV-
1) disease with highly active antiretroviral therapy (HAART)
has enormous clinical beneﬁts; however, there exists the
problem of continuing emergence of drug resistance, treat-
ment adherence and serious risk of toxicities, with the
prospect of life-long antiretroviral treatment, additionally
viral reservoirs persist in several sequestered sites such as the
central nervous system (CNS) and testis. Therefore, develop-
ing strategies that treat HIV infection and eliminate persis-
tent viral reservoirs are needed and gene therapy approaches
such as RNA interference (RNAi) have emerged as a thera-
peutic possibility for the elimination of HIV-1 [1–3].
RNAiworkseitherthroughbindingwithHIV-1toinhibit
provirus integration into cellular genome or with mRNA
products to inhibit genes that play a vital role in HIV-1 infec-
tivity by knocking down the virulence capacity of the virus
[2, 3]. RNAi is a highly potent mechanism of posttranscrip-
tional gene silencing which is mediated by sequence-speciﬁc
siRNAs, which can eﬀectively down regulate expression of
either a cellular RNA target molecules by selective degrada-
tion of mRNAs [4–6]. Viral replication can be successfully
inhibited using siRNA; however, designing a functional
siRNAthattargetsahighlydivergentviruscanbechallenging
[1–5]. Recently, a very elegant and comprehensive study by
Naito et al. analyzed several promising siRNA sequences of
near full length HIV-1 group M strains from the Los Alamos
sequence database and selected a set of optimal antiviral
siRNA [7, 8]. Delivery of optimal amounts of these synthetic
antiviral siRNAs by transfection into cultured cells can
eﬀectively inhibit HIV-1 infections; however, the antiHIV-
1e ﬀects of these delivery methods are transient due to the
degradation and dilution of siRNAs during cell division.
A major hurdle limiting the use of the gene silencing
technology is the lack of methods to safely and eﬃciently2 Pathology Research International
deliver siRNA molecules to target cells/tissues. In the free
form, siRNA molecules have a very short half life in
physiological conditions, owing to their vulnerability for
degradation by endogeneous nucleases. Therefore, they need
macromolecular carriers (vectors) that will not only protect
them from degradation in the biological milieu, but also
steer them to desired cells/tissues as well as facilitate their
cellularentry.Nanoparticlesurfacescanbeeasilymodiﬁedto
incorporate cationic charges, which will facilitate their stable
electrostatic complexation with anionic genetic materials
such as siRNA, for the purpose of targeted gene deliv-
ery/silencing [9–11]. HIV-1 nanotherapeutics can increase
drug solubility, enhance systemic bioavailability, and at the
same time oﬀer multifunctionality.
In the current study, we have used a synthetic siRNA
(si510) described by Naito et al. [7, 8] which is a highly
eﬀective siRNA against divergent HIV-1 strains which targets
the poly A/TAR (transactivator of the HIV-1 LTR) site and
successfully targets viral transcripts and achieves eﬀective
viral inhibition. HIV-1 TAR RNA is the binding site of the
viral protein Tat, the transactivator of the HIV-1 LTR (long
terminal repeat). It is present at the 5  end of all HIV-1
spliced and unspliced mRNAs in the nucleus as well as in
the cytoplasm. A TAR-speciﬁc RNA will aﬀect the viral and
cellular binding factors thereby decreasing virion production
and eﬀectively inhibit viral replication [12]. HIV-1 contains
duplicated long terminal repeat (LTR) sequences ﬂanking
the proviral genome. These LTRs contain identical poly(A)
(polyadenylation) signals, which are both transcribed into
RNA, to allow eﬃcient viral expression [12]. Thus the si510
siRNA that targets both the poly A/TAR can eﬀectively sup-
press viral replication. Naito et al. reported that the siRNA
transfectionsusingthesi510sequencethatweredoneintheir
studyweredoneusingacommerciallyavailablereagentLipo-
fectamine (Invitrogen, CA) and that this transfection was
transient in nature and that the percentage decrease in viral
replication was >90%, 48 hours posttransfection [7]. The
goalofthecurrentinvestigationtoevaluateifcomplexingthe
si510 siRNA to a nanoparticle such as a quantum rod (QR)
would eﬀectively suppress viral replication for a extended
period of time. In addition to eﬃcacy, the dose and time
kinetics of this siRNA nanoplex was evaluated in the HIV-
1-infected monocytic cell line THP-1. We believe that the
resultsofthisstudywillattesttothefactthatnanotechnology
can play a pivotal role in HIV-1 therapeutics.
2. Methods
2.1. Study Design. Following synthesis and characterization
of the nanoplexes (QR-si510 siRNA complex), we evaluated
their uptake in vitro cultured monolayers of an HIV-1-
infected monocytic cell line THP-1 using confocal imaging.
THP-1 cells were treated with various concentrations of the
si510 siRNA ranging from 5nM to 100nM over a range of
time periods from 6hr to 1 week posttransfection and the
antiviraleﬃcacythenanoplexeswastested.Twoindependent
methods were used to evaluate antiviral eﬀects: (1) the
measurement of p24 antigen levels using a commercially
available p24 ELISA assay and (2) quantitating HIV-1 LTR-
R/U5 gene expression using quantitative real-time PCR.
2.2. Synthesis and Aqueous Dispersion of the QRs Terminated
with Carboxyl Groups. The formation of the Cadmium (Cd)
Selelinum(Se)CdSecorenanocrystals,andthinlayerofZinc
Sulﬁde (ZnS) shell (<1.5nm) is grown over the nanocrystal
core. CdS/ZnS graded shell on CdSe QRs in organic media
w a sc a r r i e do u ta sd e s c r i b e db yY o n ge ta l .[ 13]. To form
the nanocrystal core, 6mmol cadmium oxide (CdO) was
dissolved in 10mL of oleic acid at 280◦C, producing a
homogeneous reaction mixture of cadmium complex. Then,
a solution of selenium (Se) precursor was injected into the
reactionmixture.TheSe:Cdmolarratiowas1:3.Thelength
of reaction time following the injection determines the ﬁnal
size of the nanocrystals. The CdSe nanocrystals were then
puriﬁed by precipitation from the reaction mixture with
ethanol followed by centrifugation. For the growth of a ZnS
shell over the CdSe cores, the CdSe cores were dispersed
in 5g of TOPO at 250◦C. A mixture of diethylzinc (Et2Zn)
and hexamethyldisilathiane ((TMS)2S) (Zn:S = 1:1molar
ratio) were mixed with Trioctylphosphine (TOP) and the
solution precursor was added dropwise into the CdSe core
nanocrystals reaction mixture at 250◦C. After ∼20 minutes
of heating, the heating mantle was removed, and then
the reaction mixture was air cooled to room temperature.
Following their synthesis, the CdSe/CdS/ZnS QRs were dis-
persed in aqueous media by coating with mercaptosuccinic
acid (MSA). Brieﬂy, 3mmol of MSA was dissolved in 10mL
ofchloroformundervigorousstirring.Afterstirringfor10to
15 minutes, 2mL of concentrated (∼40mg/mL chloroform)
CdSe/CdS/ZnS QR dispersion was added into this mixture.
Thissolutionwasstirredovernightatroomtemperature.The
QRs were separated from the surfactant solution by addition
of ethanol and centrifugation. The red-brownish precipitate
was redispersed in 10mL HPLC water and the solution was
further ﬁltered using a syringe ﬁlter with a pore diameter of
0.45μm. The QRs have relatively good colloidal stability and
noprecipitationwasobservedafterseveralmonthsofstorage
[13–15].
2.3. Physical Characterization of QRs. The physical prop-
erties of the nanoplex were established using transmission
electron microscopy (TEM), dynamic light scattering (DLS),
spectrophotometry and spectroﬂuorimetry. TEM was used
to determine the particle size and size distribution. The
aqueous dispersion of the nanoparticles was drop cast on a
TEM copper grid (electron microscopy sciences, Inc.) and
visualized using a JEOL JEM 2020 electron microscope. DLS
measurements were carried out using a Brookhaven 90Plus
particle size analyzer, with a scattering angle of 90◦.U V - v i s
absorptionspectrawererecordedusingaShimadzuUV-3101
PCspectrophotometer,usingaquartzcuvettewith1cmpath
length. Fluorescence spectra were recorded on a Fluorolog-3
(Jobin Yvon, Longjumeau, France) spectroﬂuorimeter.
2.4. Cell Viability Measurement Using an MTT (3-(4,5-Dime-
thylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide, a Tetra-
zole) Assay. MTT cell proliferation assay measures thePathology Research International 3
reduction of a tetrazolium component (MTT) into an
insoluble formazan product by the mitochondria of viable
cells. The MTT assay is a quantitative, sensitive detection of
cell proliferation since it measures the growth rate of cells
by virtue of a linear relationship between cell activity and
absorbance. Typically 10,000 cells suspended in 100μLo f
media were incubated with 10μLo fM T Tr e a g e n t( C a t#
30-1010K; ATCC) for approximately 3 hours, followed by
additionofadetergentsolutiontolysethecellsandsolubilize
the colored crystals. Colorimetric detection was done at a
wavelength of 570nm. The amount of color produced is
directly proportional to the number of viable cells.
2.5. Determination of the Delivery of Nanoplexes into THP-1
Cells. Nanoplexes (QD-siRNA) are discrete spheres, having
a mean size of 15–20nm. They are suﬃciently small to
diﬀuse into cells by endocytosis and favor nucleic acid
transfer and release from the endosome across the nuclear
membrane. Nanoplex suspensions are prepared by adding 5–
100nM si510 siRNA/10ul volume to 20μLo fQ Rs o l u t i o n
suspended in a total of 200μL of serum-free media to permit
complexformationfor15minatroomtemperaturefollowed
by addition of the nanoplex to the THP-1 cells plated in
35mm glass bottom culture plates. Commercial transfection
reagent, Lipofectamine (Invitrogen, Carlsbad, CA) is used as
a control and used according to the manufacturer’s protocol.
Cells are cultured in an incubator (VWR Scientiﬁc, model
2400) at 37◦C in a humidiﬁed atmosphere of 5% CO2 for a
period ranging from 12hr to 1 week posttransfection.
2.6. Imaging of Nanoparticles. A Nikon Eclipse TE2000
microscopeequippedwiththeNuanceGNIRimagingsystem
(Cambridge Research & Instrumentation Inc., Cambridge,
MA) was employed for cell imaging. This imaging system
is capable of multispectral (wavelength-resolved) imaging
in the range of 500–950nm. Custom-designed ﬁlter cubes,
with corresponding dichroic and emission ﬁlters acquired
from Omega Optical, were used to cut oﬀ the excitation light
and obtain high contrast ﬂuorescence images. Additionally,
a water-immersion objective lens (Nikon, Fluor 60X, NA1.0)
is used for cell imaging.
2.7. Cell Line. Monocytic THP-1 cells (American Type Cul-
ture Collection [ATCC], Manassas, VA); were maintained at
37◦C, under 5% CO2 in RPMI 1640 medium supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS)
(Sigma, St.Louis, MO), penicillin (100units/mL), strepto-
mycin (100mg/mL), and L-glutamine (2 mM). THP-1 cells
areculturedasasingle-cellsuspensionculturesandweresplit
at a ratio of 1:4 once a week.
2.8. HIV-1 Infection of THP-1. Undiﬀerentiated THP-1 cells
are susceptible to infection by T-tropic human immun-
odeﬁciency virus type 1 (HIV-1) isolates that use the
coreceptor CXCR4 (X4 strains). Undiﬀerentiated THP-1
(1 × 106 cells/mL) were infected for 3 hours with HIV-
1IIIB (NIH AIDS Research and Reference Reagent Program)
at a concentration of 10 3.0TCID50/mL cells, equivalent to
10ng viral isolate/mL of culture media. Following that,
the infected cells were washed with Hanks buﬀered saline,
reconstituted in RPMI media (fortiﬁed with 10% FBS) and
incubated at 37◦C/5% CO2 for 7 days. Levels of p24 in the
culture supernatants were measured using a commercially
available p24 ELISA kit (Zeptometrix, Buﬀalo, NY) 7 days
postinfection. These infected THP-1 cells were then washed
and reconstituted in fresh culture medium and used for
evaluating the antiHIV-1 eﬃcacy of the nanoplexes.
2.9. p24 ELISA. HIV-1 infection was monitored by the
viral p24 level in harvested cell culture supernatants,
using enzyme-linked immunosorbent assay (ELISA) plates
obtained from a commercial vendor (Zeptometrix Buﬀalo,
NY). The results are expressed in pg/mL as the mean and
standard deviation (SD) of duplicate determinations from
two wells.
2.10. Real-Time Quantitative PCR (Q-PCR). Cytoplasmic
RNA was extracted by an acid guanidinium-thiocyanate-
phenol-chloroform method using Trizol reagent (Invitrogen,
Carlsbad, CA) [16]. The amount of RNA was quantiﬁed
using a Nano-Drop ND-1000 spectrophotometer (Nano-
Drop, Wilmington, DE) and the isolated RNA was stored
at −80◦C until used. The LTR-R/U5 region represents early
stages of reverse transcription of HIV-1. Following conver-
sion of RNA to cDNA using reverse transcription, relative
abundance of mRNA species was quantiﬁed by real-time
quantitative PCR using the LTR/RU5-speciﬁc primers and
the Brilliant SYBR green QPCR master mix (Stratagene Inc,
La Jolla, CA; Cat# 600548-51). The followings are the primer
sequences used for LTR/RU5 (Forward primer 5 -TCT-
CTCTGGTTAGACCAGATCTG-3  and Reverse primer 5 -
ACTGCTAGAGATTTTCCACACTG-3 ). Relative expres-
sion of mRNA species was calculated using the comparative
CT method [17]. All data were controlled for quantity of
RNA input by performing measurements on an endogenous
reference gene, β-actin. In addition, results obtained on RNA
from treated samples were normalized to results obtained
on RNA from the control, untreated sample. Results were
expressed as transcript accumulation index (TAI) [17, 18].
This calculation assumes that all PCR reactions are taking
place with 100% eﬃciency.
3. Results
3.1. Characterization of the Nanoplexes. The physical proper-
ties of the nanoparticle formulations are usually established
using the following techniques: (a) dynamic light scattering
to estimate the hydrodynamic diameter and surface charge
of the aqueous dispersed nanoparticles, (b) transmission
electron microscopy (TEM) to determine particle size
and size distribution, and (c) evaluation of the spectral
properties of the ﬂuorescent nanomaterials using simple
spectrophotometry and spectroﬂuorimetry. Figure 1 shows
the size-distribution of the QR-siRNA nanoplex via TEM
and DLS measurements. TEM image (Figure 1(a)) shows
the rods with average length and diameter of 15nm.4 Pathology Research International
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Figure 1: QR-si510 siRNA nanoplex characterization: Representative ﬁgures of (a) Transmission electron microscope image of nanoplexes
showingthattheaveragediameterofthenanoplexis ∼15–20nm(barscale=50nm).Noaggregationwasobservedafternanoplexformation.
(b) Absorption (red line) and Emission spectra (green line) of QR-si510 siRNA nanoplexes.
Figure 1(b) shows the absorption and emission spectra of
the free siRNA and the siRNA bound to the QR with the
QR emission wavelength around ∼620nm. Transmission
electron microscopy (TEM) images of nanoplexes show that
they remain as individual particles with a diameter of ∼15–
20nm (Figure 1(a)). It can be visualized from the TEM that
siRNA complexation did not cause any aggregation of the
QRs. The concentration of these positively charged QRs was
approximately 0.1mg/mL and the optimal concentration of
QR that was used to conjugate with the si510 HIV-1 siRNA
to form a nanoplex was 200pg.
3.2. Eﬀect of the QR-si510 HIV-1siRNA Nanoplex on Cell
Viability in THP-1 Cells. An MTT assay was done to evaluate
the eﬀect of the nanoplexes on cell viability of the THP-1
cells. Cell viability was also tested in the THP-1 cells prior
to being infected by HIV-1 as well as after 7 days post
infection and over 99% viability was observed in cells prior
to be treated with the nanoplexes. THP-1 cell viability was
measuredaftertreatmentwiththenanoplexesat12,24,96hr,
and upto 1 week posttransfection using the maximum dose
(100nM) of QR-si510 HIV-1 siRNA. Our results (Figure 2)
show greater than 90% viability in THP-1 cells treated with
QR-si510 HIV-1 siRNA nanoplexes and under all treatment
conditions for up to 1 week. These results demonstrate that
the QR-mediated delivery of siRNA did not produce any
appreciable cytotoxicity in THP-1 cells.
3.3. Eﬀect of the QR-si510 HIV-1siRNA Nanoplex on HIV-1
Replication. The ultimate goal of our studies was to evaluate
the nanoplex uptake by the THP-1 cells and examine the
eﬃcacy of the nanoplex in inhibiting HIV-1 viral replication
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Figure 2: The time-dependent cytotoxicity of QR-si510 siRNA
nanoplex on THP-1 cells using the MTT assay. Our results show
absence of any toxicity in THP-1 monocytic cultures treated
with lipofectamine transfected scrambled siRNA, Lipofectamine
transfected si510 HIV-1 siRNA and the QR-si510 siRNA nanoplex
as compared to the untransfected control over a 12hr to 1 week
time period. The concentration of both the scrambled siRNA and
the si510 HIV-1 siRNA were 10nM. Also included in the MTT
assay were THP-1 cells not treated with the HIV-1 virus (no
virus control). The results shown are mean ± SD of 3 separate
experiments.
by measuring the antiviral activity in the cells and culture
supernatants.TodeterminethenanoplexuptakebytheTHP-
1 and the dose and time kinetics of the nanoplex THP-1Pathology Research International 5
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Figure 3: The dose-dependent kinetics of QR-si510 siRNA
nanoplex on HIV-1-infected THP-1 cells. THP-1 monocytic cul-
tures were treated with lipofectamine transfected scrambled siRNA
(5–100nM), Lipofectamine transfected si510 HIV-1 siRNA (5–
100nM) and the QR-si510 siRNA (5–100nM) nanoplex for a
48hr time period and the p24 production was measured in the
supernatants at the end of the incubation period using a com-
mercially available p24 ELISA kit. Untransfected HIV-1-infected
THP-1 and the non-HIV-1-infected THP-1 cells (nonvirus control)
were the experimental controls. The lipofectamine was used as per
manufacturer’s protocol. Our results show that 10nM of the QR-
si510 HIV-1siRNA nanoplex was optimal in achieving almost 85%
suppression of viral replication. The results shown are mean ± SD
of 3 separate experiments.
cells were treated with various concentrations of the si510
HIV-1siRNA ranging from 5nM to 100nM over a range of
time periods from 6hr to 1 week posttransfection and the
antiviral eﬃcacy the nanoplexes was tested. At the end of the
incubation period, the THP-1 cells and culture supernatants
were harvested and the antiviral activity was measured using
the p24 ELISA assay, as well as gene expression of HIV-1 LTR
was quantitated in the RNA extracted from the THP-1 cells
using real-time PCR.
The results of our dose response experiments (Figure 3)
show a signiﬁcant decrease in HIV-1 p24 production in HIV-
1-infected THP-1 cells transfected with the QR-si510 HIV-
1siRNA nanoplexes as compared to HIV-1-infected THP-1
cells transfected with a commercially available transfection
reagent Lipofectamine (Invitrogen, Carlsbad, CA). No sig-
niﬁcant diﬀerences in p24 levels was observed when THP-1
c e l l sw e r et r e a t e dw i t hd i ﬀerent concentration of si510 HIV-
1siRNA which ranged from 5nM to 100nM. Comparisons
between the untransfected control and the QR-si510 HIV-1
siRNA nanoplex transfected THP-1 cells show a signiﬁcant
decrease in p24 production. The p24 levels in cells treated
with 5, 10, 40, 80, and 100nM concentrations of si510
HIV-1 siRNA were 159 ± 9.6pg/mL, 111 ± 10.9pg/mL,
102 ± 11.3pg/mL, 89 ± 8.3pg/mL and 91 ± 9.6pg/mL,
respectively, that corresponded to a 79.05% decrease (P<
.001), 84.63% decrease (P<. 001), 85.65% decrease (P<
.001), 88.15% decrease (P<. 0001) and 87.69% decrease
(P<. 0001) in viral replication as measured by p24
production. While the concentrations of the si510 HIV-1
siRNA varies from 5–100nM, the QR concentration in the
nanoplexeswasconstantandwas200pg.Inourtimekinetics
experiments we used the optimal 10nM concentration of
si510 HIV-1 siRNA. Comparisons between the untransfected
control and the QR-si510 HIV-1 siRNA nanoplex transfected
THP-1 cells at 12, 24, 48, 96 and 1 week posttransfection
showed a signiﬁcant decrease in p24 production as early as
12hrs posttransfection (Figure 4). The p24 levels in THP-
1 cells at 12, 24, 48, 96hr, and 1 week posttransfection
were 114 ± 10.5pg/mL, 122 ± 11.2pg/mL, 76 ± 9.4pg/mL,
72 ± 8.7pg/mL and 64 ± 6.3pg/mL, respectively, and
corresponded to a 85.33% decrease (P<. 0001), 83.93%
decrease (P<. 0001), 90.04% decrease (P<. 0001),
89.79% decrease (P<. 0001) and 91.00% decrease (P<
.0001) in viral replication as measured by p24 production.
The QR concentration in the nanoplex was 200pg. The
results of our time kinetics experiments show that 48hrs
posttransfection, a 90% suppression of viral replication was
observed(Figure 3)andthissuppressionwasobservedeven1
week posttransfection. The 48hr time point was determined
to be the optimal time for transfection with the nanoplex, as
a 90% decrease in p24 production was observed at that time
point.
Additional experiments to determine changes in viral
replication by measuring HIV-1 LTR gene expression using
real-time PCR were done using 10nM concentration of the
QR-si510 HIV-1 siRNA nanoplex at various time points
ranging from 12hr to 1 week posttransfection. The results
of our HIV-1 LTR gene expression studies show a signiﬁcant
decreaseinHIV-1LTRgeneexpressioninTHP-1cellstreated
with the 10nM QR-si510 HIV-1siRNA nanoplex at 12, 24,
48, 96hr, and 1 week posttransfection as compared to the
untransfected THP-1 cells and also the scrambled control.
The percentage decrease in HIV-1 LTR gene expression was
91%(TAI=0.11 ±0.02versus0.91 ±0.05,(P<. 0001)),86%
(TAI=0.14 ±0.06versus0.89 ±0.03(P<. 0001)),92%(TAI
= 0.08 ± 0.03 versus 0.90 ± 0.07 (P<. 0001)), 92% (TAI =
0.08 ± 0.05 versus 0.88 ± 0.03 (P<. 0001)), and 91% (TAI =
0.09 ± 0.04 versus 0.94 ± 0.08 (P<. 0001)) as compared to
the scrambled control (Figure 5). The percentage decrease in
HIV-1 LTR gene expression in THP-1 cells treated with the
10nM of si510 HIV-1siRNA transfected with Lipofectamine
at 12, 24, 48, 96hr, and 1 week posttransfection were 60%
(TAI = 0.40 ± 0.09 versus 0.91 ± 0.05, (P<. 001)), 69%
(TAI = 0.31 ± 0.07 versus 0.89 ± 0.03 (P<. 001)), 77% (TAI
= 0.23 ± 0.05 versus 0.90 ± 0.07 (P<. 001)), 51% (TAI =
0.49 ± 0.11 versus 0.88 ± 0.03 (P<. 004)), and 37% (TAI
= 0.63 ± 0.06 versus 0.94 ± 0.08 (P<. 006)), respectively,
as compared to the scrambled control. These results conﬁrm
that the QR nanoparticles are a more eﬀective than the
commercially available transfection agent lipofectamine in
not only delivering siRNA but also suppressing HIV-1 viral
replication for a prolonged period of time.
3.4. Imaging of Nanoparticles. The cellular uptake of the QR-
siRNA nanoplexes was studied using confocal microscopy.6 Pathology Research International
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Figure 4: The dose-dependent kinetics of QR-si510 siRNA
nanoplex on HIV-1-infected THP-1 cells. THP-1 monocytic cul-
tures were treated with lipofectamine transfected scrambled siRNA
(10nM), Lipofectamine transfected si510 HIV-1 siRNA (10nM)
and the QR-si510 siRNA (10nM) nanoplex for time period ranging
from 12hr to 1 week posttransfection. At the end of the incubation
period, the p24 production was measured in the supernatants
usingacommerciallyavailablep24ELISAkit.UntransfectedHIV-1-
infected THP-1 and the non-HIV-1-infected THP-1 cells (nonvirus
control) were the experimental controls. The concentration of both
the scrambled siRNA and the si510 HIV-1 siRNA were 10nM
and the lipofectamine was used as per manufacturer’s protocol.
Our results showed that 90% suppression of viral replication was
observed 48hr posttransfection and that further this suppression
was observed even 1 week posttransfection. The results shown are
mean ± SD of 3 separate experiments.
Figure 6(a) shows the confocal microscopic imaging and the
local spectra of THP-1 cells treated with functional QR-si510
HIV-1siRNA nanoplexes. Confocal microscopy images were
obtained with laser excitation at 405nm. Figure 6(a) shows
the representative local spectra obtained from diﬀerent
points in the confocal images from cells. The red labeling
of THP-1 cells conﬁrms the ﬂuorescence signal is localized
to the QR si510 HIV-1siRNA nanoplexes which is evident
from the sharp emission spectra peaking around 625nm.
Additionally, it is important to note that the cellular autoﬂu-
orescence which is normally located around 500nm shows
no interference with the emission from QRs. Our results
show uptake of the QR-si510 HIV-1siRNA nanoplexes by
the THP-1 cells at 12, 48, 96hr, and 1 week posttransfection
(Figure 6(b) (A)–(J)).
3.5. Statistical Analysis. An Independent t-test or one-
way ANOVA was applied to compare changes between
transfected and untransfected groups. Comparison among
the means was performed with the post hoc Bonferroni
analysis test using the Prism statistical analysis software
(GraphPad Software, Inc. La Jolla, CA). The quantitative
data are presented as mean ± SD unless speciﬁed otherwise.
Statistical signiﬁcance was considered at P<. 05.
0
0.2
0.4
0.6
0.8
1
1.2
12hr 24hr 48hr 96hr 1week
T
r
a
n
s
c
r
i
p
t
a
c
c
u
m
a
t
i
o
n
i
n
d
e
x
(
T
A
I
) HIV-1 LTR gene expression
Untransfected
Lipofectamine-scrambled siRNA
Lipofectamine-si510 siRNA
QR-si510 siRNA
91%
86%
92% 92% 91%
60%
69%
77%
51%
37%
P<. 0001
P<. 0001 P<. 0001 P<. 0001
P<. 0001
P<. 001
p<. 001
P<. 001
P<. 004
P<. 006
Figure 5: Eﬀect of QR-si510 siRNA nanoplex on LTR/RU5
gene expression in HIV-1-infected THP-1 cells. THP-1 monocytic
cultures were treated with lipofectamine transfected scrambled
siRNA (10nM), Lipofectamine transfected si510 HIV-1 siRNA
(10nM)andtheQR-si510siRNA(10nM)nanoplexfortimeperiod
ranging from 12hr to 1 week posttransfection. At the end of the
incubation period, RNA was extracted, reverse transcribed and the
LTR/RU5 gene expression quantitated using Q-PCR. Our results
show a signiﬁcant decrease in HIV-1 LTR gene expression in HIV-
1-infected THP-1 cells treated with the 10nM QR-si510 HIV-
1siRNA nanoplex at 12, 24, 48, 96hr, and 1 week posttransfection
as compared to the untransfected THP-1 cells and the scrambled
control.Theresultsshownaremean ±SDof3separateexperiments
done in duplicate.
4. Discussion
Developing strategies that treat HIV infection and eliminate
persistent viral reservoirs are needed and gene therapy
approaches such as RNA interference (RNAi) have emerged
as a therapeutic possibility for the elimination of HIV-1
[19]. The RNAi pathway generates small interfering RNA
(siRNA) from either long double stranded stretches of RNA
or RNA hairpins, respectively, and this siRNA then guides
an eﬀector complex to a homologous sequence of mRNA
and regulates suppression of gene expression. We choose an
siRNAthattargetstheHIV-1TARelementsincethepresence
of TAR is important for activation of viral transcription by
theHIV-1Tatprotein.Recently,Naitoetal.didanexhaustive
comprehensive computational analysis where they validated
the functionality of several siRNA’s that targeted multiple
subtypes of HIV-1 and the highly conserved regions of the
HIV-genome [7, 8]. They identiﬁed several highly eﬀective
siRNA’sthathaveapotentialtotarget>90%ofHIV-1strains,
we choose an siRNA sequence from their list of highly
eﬀective siRNA’s called si510 which targets the TAR/poly A
region of the HIV-1 LTR.
The use of semiconductor nanocrystals (NCs) or so-
called quantum dots (QDs)/quantum rods (QRs) as lumi-
nescence probes for numerous biological and biomedical
applications has become an area of intense research over
the last decade [9–11, 20]. QRs oﬀer several advantages overPathology Research International 7
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Figure 6: Confocal images of THP-1 cells treated QR-si510 siRNA nanoplexes: THP-1 cells were treated with QR-si510 siRNA nanoplexes
for 12, 48, 96hr, and up to 1 week and uptake of the nanoplexes was observed using confocal microscopy. (a) Representative local emission
spectra conﬁrms that the ﬂuorescence signal in the THP-1 cells is localized to the QR si510 HIV-1siRNA nanoplexes, evident from the sharp
emission spectra peak of 625nm. (b) (A–J): Parallel Fluorescence and transmission images showing ﬂuorescence (red) staining indicating
QR-si510 siRNA nanoplex uptake by THP-1 cells.
organic dyes, including increased brightness, stability against
photobleaching, broad absorption spectra, and a tunable
and narrow emission spectrum [9, 10]. As a result, they
have demonstrated the potential to dramatically outperform
conventional organic dyes in imaging of cellular and subcel-
lular structures and in a variety of bioassays [9, 10, 13, 20].
More importantly, the surface of the QRs can be easily
functionalized to incorporate biologicals such as siRNAs,
antibodies,peptides,andproteins[20].Furthermore,thesize
of these nanobioconjugates under physiological condition
are typically less than 50nm, making these QR-based
nanoparticles ideal candidates for in vitro and in vivo studies
and applications [14, 15, 21].
In this investigation, we evaluate the speciﬁcity and
eﬃciency of QRs as nonviral gene nanocarriers for the
si510 HIV-1 siRNA that targets the TAR/poly A region of
the HIV-1 LTR thereby suppressing HIV-1 viral replication.
We validated the process of complexing the si510 HIV-1
siRNA to a quantum rod (QR) and examined the eﬃcacy,
the dose and time kinetics of this QR-si510 HIV-1 siRNA
nanoplex in suppressing viral replication in the HIV-1-
infected monocytic cell line THP-1.
Figure 1 showed the size-distribution of the QR-si510
HIV-1siRNA nanoplex via TEM and DLS measurements.
OurTEMimagesofthenanoplexesshowthatthenanoplexes
have a diameter of ∼20nm (Figure 1(a)) and that no8 Pathology Research International
aggregation of the QRs is observed demonstrating the
colloidal stability of the nanoplex. The QR’s we synthesized
are positively charged and concentration of these positively
charged QRs was approximately 0.1mg/mL. The concen-
tration of QR in the QR-si510 HIV-1 siRNA nanoplex was
200pg; however, the concentration of the siRNA within the
nanoplex ranged from 5nM to 100nM. Our data suggest
that as little as 10nM quantity of the QR-si510 HIV-1siRNA
nanoplex was optimal in achieving almost 85% suppression
of viral replication (Figure 3).
The optimal amount of QR available for complexation
with the siRNA was determined based on our previous
studies using QR that were synthesized based on similar
methodologies and had similar charged and concentration
as determined by their Optical density (OD) measurements
[14, 15, 21]. The results of our time kinetics experiments
showed that 90% suppression of viral replication was
observed 48hr posttransfection and further this suppres-
sion was observed even 1 week posttransfection (Figure 4).
Comparisons between lipofectamine and the QR’s indicate
that the QR’s are superior to lipofectamine in not only
delivering siRNA thereby suppressing HIV-1viral replication
as indicated by the signiﬁcant decrease in p24 levels and
by the signiﬁcant decrease in HIV-1 LTR gene expression
(Figure 5), but also that they are able to prolong the viral
suppression for a extended period of time possibly due to
the slow release of siRNA into the cells. Further, our imaging
studies (Figure 6) show signiﬁcant uptake of the QR-si510
HIV-1siRNA nanoplexes by the THP-1 and localization of
these nanoplex within the cell was observed even 1 week
posttransfection. Additionally, it is important to emphasize
that no signiﬁcant cell toxicity was observed when the THP-
1 cells were treated with the nanoplexes and >95% viability
was observed even 1 week posttreatment (Figure 2).
Gene therapy techniques such as siRNA possess great
potential in HIV-1 therapeutics; however, they must over-
come the key obstacle of reaching the interior of the
HIV-1-infected cells. Nanoparticles have the potential to
be a successful delivery vector for antiHIV-1 siRNA, anti-
HIV drugs since these nanoparticles can be modiﬁed to
improve the stability of the drug/genetic material in the
biological environment; and have the capacity to mediate
the biodistribution of active compounds; the ability to load,
transport, target, and release their therapeutic payloads and
can facilitate transport of these therapeutic payloads across
the blood-brain barrier (BBB). Thus, the QR-si510 HIV-
1 siRNA nanoplexes provide an advantage over current
therapeutic options, with respect to delivery and release of
genetic material to a speciﬁc cell. These studies indicate
that the nanoplex consisting of QR-si510 HIV-1 siRNA is
both safe and eﬀective in suppressing viral replication, thus
conﬁrmingthatnanotechnologywillplayasigniﬁcantrolein
future HIV-1 therapeutics.
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